AR-V7 and prostate cancer: The watershed for treatment selection?

Cancer Treatment Reviews

Volumn 43, Issue , 2016, Pages 27-35

  Ciccarese, Chiara ^a   Santoni, Matteo ^b   Brunelli, Matteo ^a   Buti, Sebastiano ^c   Modena, Alessandra ^a   Nabissi, Massimo ^d   Artibani, Walter ^a   Martignoni, Guido ^a   Montironi, Rodolfo ^b   Tortora, Giampaolo ^a   Massari, Francesco ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

^d UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Androgen receptor; Anti androgens sensitivity; AR V7; Prognostic role; Prostate cancer; Splice variant; Taxane sensitivity

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR SPLICE VARIANT 7; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; APALUTAMIDE; AZD 3514; BIOLOGICAL MARKER; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; EPI 001; EPI 506; GALETERONE; ODM 201; SEVITERONEL; TAXANE DERIVATIVE; TUMOR MARKER; UNCLASSIFIED DRUG; ABIRATERONE ACETATE; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; BRIDGED COMPOUND; ISOPROTEIN; PHENYLTHIOHYDANTOIN; TAXANE; TAXOID;

ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ALTERNATIVE RNA SPLICING; ANALOGS AND DERIVATIVES; CANCER STAGING; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; MALE; METABOLISM; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ABIRATERONE ACETATE; ALTERNATIVE SPLICING; ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NEOPLASM STAGING; PATIENT SELECTION; PHENYLTHIOHYDANTOIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN; TAXOIDS;

EID: 84976542293     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.12.003     Document Type: Review

References (87)

1. [1] Eisenberger, M.A., Walsh, P.C., Early androgen deprivation for prostate cancer?. N Engl J Med 341 (1999), 1837–1838.
2. [2] Garraway, L.A., Sellers, W.R., Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer 6 (2006), 593–602.
3. [3] Scher, H.I., Fizazi, K., Saad, F., Taplin, M.E., Sternberg, C.N., Miller, K., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 (2012), 1187–1197.
4. [4] Beer, T.M., Armstrong, A.J., Rathkopf, D.E., Loriot, Y., Sternberg, C.N., Higano, C.S., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371 (2014), 424–433.
5. [5] De Bono, J.S., Logothetis, C.J., Molina, A., Fizazi, K., North, S., Chu, L., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364 (2011), 1995–2005.
6. [6] Ryan, C.J., Smith, M.R., de Bono, J.S., Molina, A., Logothetis, C.J., de Souza, P., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368 (2013), 138–148.
7. [7] Gelmann, E.P., Molecular biology of the androgen receptor. J Clin Oncol 20 (2002), 3001–3015.
8. [8] Supakar, P.C., Song, C.S., Jung, M.H., Slomczynska, M.A., Kim, J.M., Vellanoweth, R.L., et al. A novel regulatory element associated with age-dependent expression of the rat androgen receptor gene. J Biol Chem 268 (1993), 26400–26408.
9. [9] Culig, Z., Klocker, H., Bartsch, G., Hobisch, A., Androgen receptors in prostate cancer. Endocr Relat Cancer c9 (2002), 155–170.
10. [10] Härd, T., Kellenbach, E., Boelens, R., Maler, B.A., Dahlman, K., Freedman, L.P., et al. Solution structure of the glucocorticoid receptor DNA-binding domain. Science 249 (1990), 157–160.
11. [11] Schoenmakers, E., Alen, P., Verrijdt, G., Peeters, B., Verhoeven, G., Rombauts, W., et al. Differential DNA binding by the androgen and glucocorticoid receptors involves the second Zn-finger and a C-terminal extension of the DNA-binding domains. Biochem J 314 (1999), 515–521.
12. [12] Dahlman-Wright, K., Wright, A., Gustafsson, J.A., Carlstedt-Duke, J., Interaction of the glucocorticoid receptor DNA-binding domain with DNA as a dimer is mediated by s short segment of five amino acids. J Biol Chem 266 (1991), 3107–3112.
13. [13] Matias, P.M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 275 (2000), 26164–26171.
14. [14] Bevan, C.L., Hoare, S., Claessens, F., Heery, D.M., Parker, M.G., The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol 19 (1999), 8383–8392.
15. [15] Haelens, A., Tanner, T., Denayer, S., Callewaert, L., Claessens, F., The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res 67 (2007), 4514–4523.
16. 2-terminal and steroid-binding domains. J Biol Chem 268 (1993), 19004–19012.
17. [17] Shang, Y., Myers, M., Brown, M., Formation of the androgen receptor transcription complex. Mol Cell 9 (2002), 601–610.
18. [18] Dehm, S.M., Tindall, D.J., Molecular regulation of androgen action in prostate cancer. J Cell Biochem 99 (2006), 333–344.
19. [19] Chen, C.D., Welsbie, D.S., Tran, C., Baek, S.H., Chen, R., Vessella, R., et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10 (2004), 33–39.
20. [20] Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9 (1995), 401–406.
21. [21] Koivisto, P., Kononen, J., Palmberg, C., Tammela, T., Hyytinen, E., Isola, J., et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57 (1997), 314–319.
22. [22] Grasso, C.S., Wu, Y.M., Robinson, D.R., Cao, X., Dhanasekaran, S.M., Khan, A.P., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487 (2012), 239–243.
23. [23] Hara, T., Miyazaki, J., Araki, H., Yamaoka, M., Kanzaki, N., Kusaka, M., et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63 (2003), 149–153.
24. [24] Taplin, M.E., Bubley, G.J., Shuster, T.D., Frantz, M.E., Spooner, A.E., Ogata, G.K., et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332 (1995), 1393–1398.
25. [25] Joseph, J.D., Lu, N., Qian, J., Sensintaffar, J., Shao, G., Brigham, D., et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 3 (2013), 1020–1029.
26. [26] Korpal, M., Korn, J.M., Gao, X., Rakiec, D.P., Ruddy, D.A., Doshi, S., et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov 3 (2013), 1030–1043.
27. [27] Modena, A., Ciccarese, C., Fantinel, E., Bimbatti, D., Tortora, G., Massari, F., Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide. Expert Rev Anticancer Ther 1 (2015), 1–12.
28. [28] Jenster, G., van der Korput, H.A., van Vroonhoven, C., van der Kwast, T.H., Trapman, J., Brinkmann, A.O., Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5 (1991), 1396–1404.
29. [29] Yeh, S., Lin, H.K., Kang, H.Y., Thin, T.H., Lin, M.F., Chang, C., From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A 96 (1999), 5458–5463.
30. [30] Lin, H.K., Hu, Y.C., Yang, L., Altuwaijri, S., Chen, Y.T., Kang, H.Y., et al. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem 278 (2003), 50902–50907.
31. [31] Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10 (2006), 309–319.
32. [32] Locke, J.A., Guns, E.S., Lubik, A.A., Adomat, H.H., Hendy, S.C., Wood, C.A., et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68 (2008), 6407–6415.
33. [33] Titus, M.A., Schell, M.J., Lih, F.B., Tomer, K.B., Mohler, J.L., Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11 (2005), 4653–4657.
34. [34] Chang, K.H., Li, R., Papari-Zareei, M., Watumull, L., Zhao, Y.D., Auchus, R.J., et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A 108 (2011), 13728–13733.
35. [35] Céraline, J., Cruchant, M.D., Erdmann, E., Erbs, P., Kurtz, J.E., Duclos, B., et al. Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Int J Cancer 108 (2004), 152–157.
36. [36] Libertini, S.J., Tepper, C.G., Rodriguez, V., Asmuth, D.M., Kung, H.J., Mudryj, M., Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res 67 (2007), 9001–9005.
37. [37] Hu, R., Dunn, T.A., Wei, S., Isharwal, S., Veltri, R.W., Humphreys, E., et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69 (2009), 16–22.
38. [38] Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D.E., Chen, H., et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69 (2009), 2305–2313.
39. [39] Dehm, S.M., Schmidt, L.J., Heemers, H.V., Vessella, R.L., Tindall, D.J., Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68 (2008), 5469–5477.
40. [40] Chan, S.C., Li, Y., Dehm, S.M., Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem 287 (2012), 19736–19749.
41. [41] Dehm, S.M., Tindall, D.J., Alternatively spliced androgen receptor variants. Endocr Relat Cancer 18 (2011), R183–R196.
42. [42] Zhang, H., Zhan, Y., Liu, X., Qi, Y., Zhang, G., Sartor, O., et al. Splicing variants of androgen receptor in prostate cancer. Am J Clin Exp Urol 1 (2013), 18–24 [eCollection 2013].
43. [43] Sun, S., Sprenger, C.C., Vessella, R.L., Haugk, K., Soriano, K., Mostaghel, E.A., et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120 (2010), 2715–2730.
44. [44] Zhang, X., Morrissey, C., Sun, S., Ketchandji, M., Nelson, P.S., True, L.D., et al. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One, 6, 2011, e27970.
45. [45] Xu, D., Zhan, Y., Qi, Y., Cao, B., Bai, S., Xu, W., et al. Androgen receptor splice variants dimerize to transactivate target genes. Cancer Res 75 (2015), 3663–3671.
46. [46] Le Page, C., Koumakpayi, I.H., Alam-Fahmy, M., Mes-Masson, A.M., Saad, F., Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. Br J Cancer 94 (2006), 1906–1912.
47. [47] Watson, P.A., Chen, Y.F., Balbas, M.D., Wongvipat, J., Socci, N.D., Viale, A., et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 107 (2010), 16759–16765.
48. [48] Nakazawa, M., Lu, C., Chen, Y., Paller, C.J., Carducci, M.A., Eisenberger, M.A., et al. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol 26 (2015), 1859–1865.
49. [49] Bitting, R.L., Schaeffer, D., Somarelli, J.A., Garcia-Blanco, M.A., Armstrong, A.J., The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. Cancer Metastasis Rev 33 (2014), 441–468.
50. [50] Cottard, F., Asmane, I., Erdmann, E., Bergerat, J.P., Kurtz, J.E., Céraline, J., Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells. PLoS One, 8, 2013, e63466.
51. [51] Sun, F., Chen, H.G., Li, W., Yang, X., Wang, X., Jiang, R., et al. Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors. J Biol Chem 289 (2014), 1529–1539.
52. [52] Hörnberg, E., Ylitalo, E.B., Crnalic, S., Antti, H., Stattin, P., Widmark, A., et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One, 6, 2011, e19059.
53. [53] Qu, Y., Dai, B., Ye, D., Kong, Y., Chang, K., Jia, Z., et al. Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. Sci Rep, 5, 2015, 7654.
54. [54] Dehm, S.M., Tindall, D.J., Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J Biol Chem 281 (2006), 27882–27893.
55. [55] Hu, R., Lu, C., Mostaghel, E.A., Yegnasubramanian, S., Gurel, M., Tannahill, C., et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 72 (2012), 3457–3462.
56. [56] Li, Y., Chan, S.C., Brand, L.J., Hwang, T.H., Silverstein, K.A., Dehm, S.M., Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 73 (2013), 483–489.
57. [57] Nadiminty, N., Tummala, R., Liu, C., Yang, J., Lou, W., Evans, C.P., et al. NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther 12 (2013), 1629–1637.
58. [58] Cao, B., Qi, Y., Zhang, G., Xu, D., Zhan, Y., Alvarez, X., et al. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget 5 (2014), 1646–1656.
59. [59] Mostaghel, E.A., Marck, B.T., Plymate, S.R., Vessella, R.L., Balk, S., Matsumoto, A.M., et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17 (2011), 5913–5925.
60. [60] Antonarakis, E.S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J.C., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371 (2014), 1028–1038.
61. [61] Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, Wurm C, et al. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget 2015 Apr 23. [Epub ahead of print].
62. [62] Bambury RM, Rathkopf DE. Novel and next-generation androgen receptor-directed therapies for prostate cancer: beyond abiraterone and enzalutamide. Urol Oncol 2015; pii: S1078–1439(15)00269–0.
63. [63] Myung, J.K., Banuelos, C.A., Fernandez, J.G., Mawji, N.R., Wang, J., Tien, A.H., et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest 123:7 (2013), 2948–2960.
64. [64] Andersen, R.J., Mawji, N.R., Wang, J., Wang, G., Haile, S., Myung, J.K., et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17:6 (2010), 535–546.
65. [65] Crona DJ, Milowsky MI, Whang YE. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance. Clin Pharmacol Ther. 2015 Sep 1. doi: 10.1002/cpt.256. [Epub ahead of print].
66. [66] Yaqub, F., Galeterone activity in castration-resistant prostate cancer. Lancet Oncol, 16(1), 2015, e10.
67. [67] Njar, V.C., Brodie, A.M., Discovery and development of galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. J Med Chem 58:5 (2015), 2077–2087.
68. [68] Toren, P.J., Kim, S., Pham, S., Mangalji, A., Adomat, H., Guns, E.S., et al. Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer. Mol Cancer Ther 14:1 (2015), 59–69.
69. [69] Rathkopf, D.E., Morris, M.J., Fox, J.J., Danila, D.C., Slovin, S.F., Hager, J.H., et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol 31:28 (2013), 3525–3530.
70. [70] Fizazi, K., Massard, C., Bono, P., Jones, R., Kataja, V., James, N., et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol 15:9 (2014), 975–985.
71. [71] Massard C, Penttinen HM, Vjaters E, Bono P, Lietuvietis V, Tammela TL, et al. Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: an Open-label Phase 1 Study. Eur Urol 2015 Oct 10. pii: S0302-2838(15)00964-1. doi: 10.1016/j.eururo.2015.09.046. [Epub ahead of print].
72. [72] Fizazi, K., Albiges, L., Loriot, Y., Massard, C., ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. Expert Rev Anticancer Ther 15:9 (2015), 1007–1017.
73. [73] Loddick, S.A., Ross, S.J., Thomason, A.G., Robinson, D.M., Walker, G.E., Dunkley, T.P., et al. AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther 12:9 (2013), 1715–1727.
74. [74] Omlin, A., Jones, R.J., van der Noll, R., Satoh, T., Niwakawa, M., Smith, S.A., et al. AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies. Invest New Drugs 33:3 (2015), 679–690.
75. [75] Tannock, I.F., de Wit, R., Berry, W.R., Horti, J., Pluzanska, A., Chi, K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004), 1502–1512.
76. [76] De Bono, J.S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.P., Kocak, I., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376 (2010), 1147–1154.
77. [77] Zhu, M.L., Horbinski, C.M., Garzotto, M., Qian, D.Z., Beer, T.M., Kyprianou, N., Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 70 (2010), 7992–8002.
78. [78] Darshan, M.S., Loftus, M.S., Thadani-Mulero, M., Levy, B.P., Escuin, D., Zhou, X.K., et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 71 (2011), 6019–6029.
79. [79] van Soest, R.J., de Morrée, E.S., Kweldam, C.F., de Ridder, C.M., Wiemer, E.A., Mathijssen, R.H., et al. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer. Eur Urol 67 (2015), 981–985.
80. [80] Cheng, H.H., Gulati, R., Azad, A., Nadal, R., Twardowski, P., Vaishampayan, U.N., et al. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis 18 (2015), 122–127.
81. [81] Schweizer, M.T., Zhou, X.C., Wang, H., Bassi, S., Carducci, M.A., Eisenberger, M.A., et al. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol 66 (2014), 646–652.
82. [82] Thadani-Mulero, M., Portella, L., Sun, S., Sung, M., Matov, A., Vessella, R.L., et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res 74 (2014), 2270–2282.
83. [83] Zhang G, Liu X, Li J, Ledet E, Alvarez X, Qi Y et al. Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents. Oncotarget 2015 Jun 22. [Epub ahead of print].
84. [84] Antonarakis, E.S., Lu, C., Luber, B., Wang, H., Chen, Y., Nakazawa, M., et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol 1 (2015), 582–591.
85. [85] Taplin, M.E., Balk, S.P., Has the time arrived for biomarker-directed therapy in castration-resistant prostate cancer?. JAMA Oncol 1 (2015), 577–579.
86. [86] W. Onstenk, A.M. Sieuwerts, J. Kraan, M. Van, A.J. Nieuweboer, R.H. Mathijssen, et al. Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. Eur Urol. 2015 Jul 15. pii: S0302-2838(15)00611-9. doi: 10.1016/j.eururo.2015.07.007. [Epub ahead of print].
87. [87] Roberts J, Dhillon R, Dransfield DT, Mamlouk KK, Ferrante KJ. Androgen Receptor Modulation Optimized for Response in Splice Variant (ARMOR3-SV):Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide (enz) in men expressing AR-V7 splice variant(SV), metastatic castrate resistant prostate cancer (mCRPC). J Clin Oncol 2015; 33(Suppl. 7):abstr 259.